Caricamento...
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...
Salvato in:
| Pubblicato in: | J Transplant |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Hindawi Publishing Corporation
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/ https://ncbi.nlm.nih.gov/pubmed/27807479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|